Long-term Combination Therapy with Anti-TNF plus Vedolizumab Induces and Maintains Remission in Therapy-refractory Ulcerative Colitis

Am J Gastroenterol. 2017 Oct;112(10):1621-1623. doi: 10.1038/ajg.2017.242.

Authors

Sarah Fischer¹, Timo Rath¹, Carol-Immanuel Geppert², Bernhard Manger³, Georg Schett³, Markus F Neurath¹, Raja Atreya¹

Affiliations

¹ Department of Medicine 1, Friedrich-Alexander-Universität Erlangen-Nìrnberg, Erlangen, Germany.
² Department of Pathology, Friedrich-Alexander-Universität Erlangen-Nìrnberg, Erlangen, Germany.
³ Department of Medicine 3, Friedrich-Alexander-Universität Erlangen-Nìrnberg, Erlangen, Germany.

PMID: 28978957
DOI: 10.1038/ajg.2017.242

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Monoclonal, Humanized
Colitis, Ulcerative*
Crohn Disease*
Humans
Infliximab
Tumor Necrosis Factor-alpha

Substances

Antibodies, Monoclonal, Humanized
Tumor Necrosis Factor-alpha
vedolizumab
Infliximab